People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Pharmaceuticals, Medical Devices, Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $611.8M | 2012 |
| Minerva Surgical Inc | — | Medical Devices | Series B | $167.3M | $397.4M | 2014 |
| ProNAi Therapeutics Inc | — | Biotechnology | Series C | $77.7M | $2.4B | 2014 |
| Airxpanders Inc | — | Other Health Care | Series A | $60.0M | $300.5M | 2012 |
| Neomend Inc | — | Other Health Care | Series B | $48.9M | $221.5M | 2009 |
| Vicept Therapeutics, Inc. | — | Pharmaceuticals | Series B | $22.0M | $536.9M | 2009 |
| Yaupon Therapeutics Inc | — | Pharmaceuticals | Series A | $21.6M | $256.8M | 2011 |
| Carbylan Therapeutics, Inc. | — | Other Health Care | Series A | $15.0M | $80.7M | 2012 |
| Medley Health, Inc. | — | Other Health Care | Series A | $13.0M | $30.3M | 2010 |
Albert Cha at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Albert Cha on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Stephen Tullman | 3 | 7 |
| ANAND MEHRA | 2 | 7 |
| Neal Walker | 2 | 5 |
| Christopher Powala | 2 | 3 |
| Kamil Ali-Jackson | 2 | 3 |
| David Renzi | 2 | 2 |
| DAVID M. RENZI | 2 | 2 |
| Robert Anderson | 1 | 24 |
| Ali Behbahani | 1 | 17 |
| Peter Thompson | 1 | 16 |
| Jack Nielsen | 1 | 13 |
| James Topper | 1 | 12 |
| John Nehra | 1 | 11 |
| Ketan Patel | 1 | 10 |
| David Gordon | 1 | 8 |
| Thomas Beck | 1 | 7 |
| Csaba Truckai | 1 | 7 |
| Ross Jaffe | 1 | 7 |
| Chris Ehrlich | 1 | 6 |
| Rodney Perkins | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.